EDIT - Editas Medicine, Inc.
| Previous Close | 22.83 |
| Open | 23.00 |
| Bid | 20.72 x 800 |
| Ask | 23.75 x 1800 |
| Day's Range | 22.16 - 23.11 |
| 52 Week Range | 17.80 - 38.77 |
| Volume | 602,002 |
| Avg. Volume | 732,817 |
| Market Cap | 1.098B |
| Beta (3Y Monthly) | 2.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.26 |
| Earnings Date | Aug 5, 2019 - Aug 9, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 46.71 |
- Insider Monkey•2 days ago
Is Editas Medicine, Inc. (EDIT) A Good Stock To Buy?
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the first quarter, which unveil their equity positions as of March 31. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
- GlobeNewswire•12 days ago
Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced results from a follow-up study to assess two different CRISPR genome editing strategies, one targeting the BCL11A erythroid enhancer (BC11Ae) and one targeting the beta-globin locus, for the treatment of sickle cell disease and beta-thalassemia. The Company reported the data at the 24th Congress of the European Hematology Association in Amsterdam.
- Zacks•13 days ago
Glaxo Inks Genome Research Deal With University of California
Glaxo (GSK) signs a five-year collaboration contract with the University of California to build a new laboratory for developing new medicines with the aid of CRISPR technologies.
- Motley Fool•16 days ago
Is the Newest Gene Editing Stock a Buy?
Precision BioSciences raised over $170 million in net proceeds from its initial public offering in late March.
- Zacks•17 days ago
CRISPR Therapeutics Up on Collaboration Expansion by Vertex
CRISPR Therapeutics (CRSP) is set to receive $175 million in upfront payment from Vertex following the expansion of the collaboration agreement for gene editing program to include new disease areas.
- Motley Fool•20 days ago
Why I'm Sticking With My 3 Worst-Performing Stocks of 2019 So Far
They might be this year's Bad News Bears, but I think these three stocks will be long-term winners.
- American City Business Journals•21 days ago
Life sciences VC firm Third Rock raises $770M in its largest round ever
One of Massachusetts' leading life sciences venture capital firms has raised its largest ever fund, collecting $770 million to invest in new startups. Third Rock Ventures LLC closed its fifth fundraising this week, the company stated in a press release.
- Zacks•last month
Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study
Adverum's (ADVM) stock gains as the FDA lifts the clinical hold on the second cohort of an initial stage study on lead candidate.
- Thomson Reuters StreetEvents•last month
Edited Transcript of EDIT earnings conference call or presentation 7-May-19 9:00pm GMT
Q1 2019 Editas Medicine Inc Earnings Call
- Motley Fool•last month
3 Small-Cap Biotech Stocks You Can Buy Right Now
They're risky. You'll have to wait years before any significant revenue comes in. But these biotech stocks could be huge winners.
- Zacks•2 months ago
Spectrum Pharma (SPPI) Q1 Earnings Lag Estimates, Revenues Nil
Spectrum Pharma (SPPI) misses bottom-line estimates in the first quarter. The company completes sale of its marketed portfolio in March.
- Zacks•2 months ago
IVERIC bio's (ISEE) Q1 Loss Narrows, Gene Therapy in Focus
IVERIC bio (ISEE) first-quarter earnings beat estimates. The company is focusing on developing gene therapies for treating inherited retinal diseases.
- Motley Fool•2 months ago
Editas Gears Up for a Busy 2019
With an upcoming phase 1/2 trial, new medicines in development, and new strategic collaborations, the gene-editing leader is framing an exciting year.
Motley Fool•2 months agoEditas Medicine, Inc. (EDIT) Q1 2019 Earnings Call Transcript
EDIT earnings call for the period ending May 31, 2019.
- Zacks•2 months ago
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of -5.26% and -73.30%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Editas: 1Q Earnings Snapshot
The Cambridge, Massachusetts-based company said it had a loss of 60 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•2 months ago
Editas Medicine Announces First Quarter 2019 Results and Update
- Building on focus in oncology through newly-formed partnership with BlueRock Therapeutics to develop universal allogeneic cell medicines for cancer - - EDIT-101 (AGN-151587).
- American City Business Journals•2 months ago
After $59M round, CRISPR startup launches with plans to tackle heart disease
A new gene editing company founded by two Harvard scientists and one of the men behind Editas Medicine has launched with nearly $59 million to develop a single treatment for the leading cause of death worldwide.
- Zacks•2 months ago
Geron's (GERN) Q1 Earnings Beat, Revenues Miss, Stock Up
Geron (GERN) posts narrower-than-expected loss in first-quarter 2019 but misses on revenues. Operating expenses increase on a year-over-year basis.
- Zacks•2 months ago
ImmunoGen (IMGN) Misses on Earnings & Revenues in Q1
ImmunoGen (IMGN) reports wider-than-expected loss in Q1 and misses revenue estimates.
- Simply Wall St.•2 months ago
Did Changing Sentiment Drive Editas Medicine's (NASDAQ:EDIT) Share Price Down By 27%?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! While not a mind-blowing move, it is good to see that the Editas Medicine, Inc. (NASDAQ:EDIT) shar...
- Zacks•2 months ago
Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?
Is (EDIT) Outperforming Other Medical Stocks This Year?
- Insider Monkey•2 months ago
Here is What Hedge Funds Think About Editas Medicine, Inc. (EDIT)
Is Editas Medicine, Inc. (NASDAQ:EDIT) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably but historically their consensus stock […]
- GlobeNewswire•2 months ago
Editas Medicine to Host Conference Call Discussing First Quarter 2019 Results and Corporate Update
CAMBRIDGE, Mass., April 30, 2019 -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on.
